Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

TThis is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

alt text

Multiomics and Biomarkers in Rare Diseases Supporting Development and Commercialization of Orphan Drugs

On Demand
Listen now

Orphan drugs have gained increased attention in recent years from patients, drug developers, and investors. However, developing therapeutic options for patients affected by rare genetic diseases is challenging, and incorporating additional dimensions of understanding the disease beyond genotype and phenotype is critical for success.

If you are tackling the challenges of orphan drugs in early stage development, clinical trial enrollment, or market development, listen now to learn more about How Multiomics and Biomarkers in Rare Diseases are Supporting Development and Commercialization of Orphan Drugs.

Questions addressed during the webinar:

  • How can an integrated approach using genomics, metabolomics, and proteomics be used in target discovery & validation?
  • How can biomarkers be developed rapidly to enable patient identification, recruitment, and stratification in clinical studies?
  • How can these tools be used in monitoring the response to therapy and improving health economic outcomes?
  • How can screening of high-risk populations be done accurately and cost-effectively?

CENTOGENE is dedicated to transforming the science of genetic information into solutions. We’re using our unique platform composed of a global database, biobank, and analytical tools to accelerate preclinical, clinical, and commercial programs in support of curing genetic disorders.

Listen now as we fight to improve outcomes for patients and their families.


alt text

Oved Amitay

Chief Business Officer, CENTOGENE

Oved serves as Chief Business Officer with nearly three decades of broad commercial and development experience, focusing on orphan drugs for patients with rare genetic diseases. He has the overall responsibility for the company´s pharmaceutical industry programs, including enhancing existing partnerships and establishing new collaborations to facilitate drug development and improve treatment outcomes.

Oved joined CENTOGENE from Arrett Neuroscience where he held the position of President and Chief Operating Officer, having led the company’s strategy for developing therapies for Rett syndrome. Prior to that, he served as Vice President, Head of Commercial at Alnylam Pharmaceuticals, with a lead role in the organization’s transition from a technology- platform focus to a patient-centric drug development and pre-launch enterprise. Oved had a long tenure at Genzyme Corporation (now Sanofi Genzyme) as Vice President, Strategic Development, responsible for program management, business development, market assessment, and business planning for the rare genetic diseases franchise, and as General Manager of the Gaucher and MPS business. He is also a Founding Advisor of Splisense Therapeutics, Israel. Oved holds a M.Sc., Pharmacology, from Northeastern University, Boston, MA and a B.Sc., Pharmacy, from the Hebrew University, Jerusalem, Israel.

alt text

Justin Bingham

Vice President Business Development, CENTOGENE

Justin, as Senior Vice President of Business Development, leads a global team developing our pharmaceutical partnership strategy with the goal of maximizing value through accelerating and de-risking orphan drug programs for rare genetic diseases.

Prior to CENTOGENE, Justin was the Director of Business Development at Synthetic Genomics, Inc (SGI) and responsible for pharma and life science partnerships and collaborations. Justin also led the global marketing and sales activities for SGI-DNA, Inc., a wholly owned subsidiary of SGI and life sciences company developing synthetic biology tools and technologies with global applications. He draws from more than 10 years as a cell biologist working in preclinical drug discovery first with the Genomics Institute of the Novartis Research Foundation (GNF) and then the Exploratory Technologies Group within Pfizer Research and Development.

His broad experience as a scientist and in scaling life science and biotechnology companies to meet the demands of their partners provides a unique perspective and helps CENTOGENE to build value as a company.

alt text

Dr. Peter Bauer

Chief Genomic Officer, CENTOGENE

Peter serves as CGO, combining clinical and medical understanding in genetic testing with an excellent knowledge of the latest scientific developments, based on his extraordinary experience, especially in high-throughput genetic testing using next-generation sequencing.

Peter is passionate about turning medical questions into a complete and fast analytical process, ensuring that the medically driven result is brought back to the clinician and the patient immediately.

After studying Medicine in Freiburg and Berlin, Peter worked as a resident in Neurology at Rostock, and as a resident in Human Genetics at Tübingen since 1997. He received his board certification in Human Genetics in 2006, and heads the molecular diagnostic laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. His experience ranges from medium- to high-throughput genetic analyses, including the application of next-generation sequencing in a clinical setting, genetic research in neurodegenerative disease and hereditary cancer. Peter has an extensive track record in medical and scientific publications, focusing on neurogenetics, oncogenetics, cardiogenetics, and sequencing technology. He is co-principal investigator in a large European consortium on rare neurodegenerative diseases, where he overlooks specifically gene panel, exome and genome sequencing ( Moreover, Peter is vice president of the German Society of Neurogenetics (DGNG).

Hosted by

Andrea Charles

Editor, Custom Content

Informa Pharma Intelligence

Complete the form to access on demand!

By ticking this box, you agree to receive emails such as relevant news, updates and offers from Informa Business Intelligence, and carefully selected similar products from our portfolio

By completing this form you agree CENTOGENE AG may contact you directly about industry news, products, services and events that may be of interest to you subject to their privacy policy.

You can unsubscribe from communications in the future at any time using the unsubscribe link contained in each email.